1. Academic Validation
  2. Targeting of XJB-5-131 to mitochondria suppresses oxidative DNA damage and motor decline in a mouse model of Huntington's disease

Targeting of XJB-5-131 to mitochondria suppresses oxidative DNA damage and motor decline in a mouse model of Huntington's disease

  • Cell Rep. 2012 Nov 29;2(5):1137-42. doi: 10.1016/j.celrep.2012.10.001.
Zhiyin Xun 1 Sulay Rivera-Sánchez Sylvette Ayala-Peña James Lim Helen Budworth Erin M Skoda Paul D Robbins Laura J Niedernhofer Peter Wipf Cynthia T McMurray
Affiliations

Affiliation

  • 1 Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.
Abstract

Oxidative damage and mitochondrial dysfunction are implicated in aging and age-related neurodegenerative diseases, including Huntington's disease (HD). Many naturally occurring antioxidants have been tested for their ability to correct for deleterious effects of Reactive Oxygen Species, but often they lack specificity, are tissue variable, and have marginal efficacy in human clinical trials. To increase specificity and efficacy, we have designed a synthetic antioxidant, XJB-5-131, to target mitochondria. We demonstrate in a mouse model of HD that XJB-5-131 has remarkably beneficial effects. XJB-5-131 reduces oxidative damage to mitochondrial DNA, maintains mitochondrial DNA copy number, suppresses motor decline and weight loss, enhances neuronal survival, and improves mitochondrial function. The findings poise XJB-5-131 as a promising therapeutic compound.

Figures
Products